Stock DNA
Medical Specialties
USD 1,098 Million (Micro Cap)
NA (Loss Making)
NA
99.31%
0.59
-41.25%
8.41
Revenue and Profits:
Net Sales:
72 Million
(Quarterly Results - Dec 2024)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
11.98%
0%
11.98%
6 Months
141.96%
0%
141.96%
1 Year
33.71%
0%
33.71%
2 Years
-28.63%
0%
-28.63%
3 Years
-29.09%
0%
-29.09%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Paragon 28, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
20.21%
EBIT Growth (5y)
-221.26%
EBIT to Interest (avg)
-6.78
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.59
Sales to Capital Employed (avg)
0.88
Tax Ratio
2.17%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
71.90%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
8.41
EV to EBIT
-28.80
EV to EBITDA
-52.83
EV to Capital Employed
5.67
EV to Sales
4.58
PEG Ratio
NA
Dividend Yield
99.31%
ROCE (Latest)
-19.67%
ROE (Latest)
-41.25%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Bearish
Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Dec 2024
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 41 Schemes (15.73%)
Foreign Institutions
Held by 63 Foreign Institutions (3.48%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY
Dec'24
Dec'23
Change(%)
Net Sales
71.70
60.60
18.32%
Operating Profit (PBDIT) excl Other Income
-1.50
-14.60
89.73%
Interest
3.00
2.00
50.00%
Exceptional Items
-0.50
-4.10
87.80%
Consolidate Net Profit
-11.10
-29.30
62.12%
Operating Profit Margin (Excl OI)
-89.70%
-323.40%
23.37%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2024 is 18.32% vs 17.67% in Dec 2023
Consolidated Net Profit
YoY Growth in quarter ended Dec 2024 is 62.12% vs 24.48% in Dec 2023
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
256.20
216.40
18.39%
Operating Profit (PBDIT) excl Other Income
-22.20
-30.10
26.25%
Interest
13.30
5.20
155.77%
Exceptional Items
-0.80
-4.80
83.33%
Consolidate Net Profit
-54.60
-57.50
5.04%
Operating Profit Margin (Excl OI)
-159.20%
-211.00%
5.18%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 18.39% vs 19.29% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 5.04% vs 14.56% in Dec 2023
About Paragon 28, Inc. 
Paragon 28, Inc.
Medical Specialties
No Details Available.
Company Coordinates 
No Company Details Available






